Zhejiang Hisun Pharmaceutical: Give up the pharmaceutical distribution raw material business, leading to a decline in H1 revenue. Sales of Olsalazine increased significantly compared to the same period last year.
①At the earnings conference, the CFO of Zhejiang Hisun Pharmaceutical explained that the decline in H1 revenue was due to the company's abandonment of low-margin pharmaceutical distribution raw material business and other factors. ②President Xiao Weihong addressed questions about the growth in endocrine drug revenue and the future business model of the animal health sector.
The net profit of Harbin Pharmaceutical Co., Ltd. has more than tripled in the three quarters: driven by the recovery of health products, sustainability is yet to be tested
Back to normal
People who lose weight aren't in a hurry; are pharmaceutical companies in a hurry? The chairman of Borui Pharmaceutical claims to have “tried drugs on his own” to lose 30 pounds or is mired in controversy
Insane.
Huahai Pharmaceutical's refinancing bets on 100 tons of COVID-19 drugs: disputes over economic benefits still exist
In the context of tightening refinancing, the rationality and necessity of refinancing for A-share companies has received widespread attention from the market. Recently, Huahai Pharmaceutical (600521.SH) updated the refinancing inquiry response materials. Among them, the issue of the rationality of estimating the economic benefits of the production expansion plan attracted the attention of the regulatory authorities. According to the application materials, Huahai Pharmaceutical plans to raise 1,560 billion yuan to invest in the construction of “digital intelligent manufacturing of formulations”, “multi-functional production platform for specialty APIs such as antiviruses” projects, and supplementary liquidity. Among them, the “Multifunctional Production Platform for Antiviral and Other Special APIs” project involves “an annual output of 100 tons
The suspected pollution of Erkang Pharmaceuticals' Cambodian factory was evicted due to a local request and an announcement will be made later
Serious pollution
China's National Medical Products Administration In Late December Met With Several Chinese Drugmakers Including Zhejiang Huahai Pharmaceutical And CSPC Pharmaceutical Group To Discuss Preparations Needed To Make A Generic Version Of Paxlovid